Antiamyloid antibodies have been used to reduce cerebral amyloid-beta (AB) load in patients with Alzheimer's disease. We applied focused ultrasound with each six monthly aducanumab infusions to temporarily open the blood-brain barrier with the goal of enhancing amyloid removal in selected brain regions in three participants over a period of 6 months. The reduction in the level of A/3 was numerically greater in regions treated with focused ultrasound than in the homologous Mediregions in the contralateral hemisphere that were not treated with focused ultra-sound, as measured by fluorine-18 florbetaben positron-emission tomography. Cognitive tests and safety evaluations were conducted over a period of30 to 180 days Uniafter treatment. (Funded by the Harry T. Mangurian, Jr. Foundation and the West Virginia University Rockefeller Neuroscience Institute). [ABSTRACT FROM AUTHOR]